UPSTREAM BIO, INC. Operating Cash Flow
UPSTREAM BIO, INC. (UPB) reported Operating Cash Flow of -$83.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- UPSTREAM BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$35.62M.
- UPSTREAM BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$47.85M.
- UPSTREAM BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$30.63M.
- UPSTREAM BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$22.24M.
- UPSTREAM BIO, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$133.28M.
- UPSTREAM BIO, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$59.17M.
- UPSTREAM BIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$37.93M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$35.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$83.47M 10-Q · filed 2026-08-11 | -$114.10M derived: sum of 3 quarters · filed 2026-08-11 | -$136.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$47.85M 10-Q · filed 2026-05-13 | -$78.48M derived: sum of 2 quarters · filed 2026-05-13 | -$100.72M derived: sum of 3 quarters · filed 2026-05-13 | -$139.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$30.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$52.87M derived: sum of 2 quarters · filed 2026-03-26 | -$92.11M derived: sum of 3 quarters · filed 2026-08-11 | -$133.28M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$22.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$61.48M derived: sum of 2 quarters · filed 2026-08-11 | -$102.64M 10-Q · filed 2025-11-05 | -$122.26M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$39.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$80.40M 10-Q · filed 2026-08-11 | -$100.02M derived: sum of 3 quarters · filed 2026-08-11 | -$113.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$41.16M 10-Q · filed 2026-05-13 | -$60.78M derived: sum of 2 quarters · filed 2026-05-13 | -$74.74M derived: sum of 3 quarters · filed 2026-05-13 | -$82.78M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$19.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$33.57M derived: sum of 2 quarters · filed 2026-03-26 | -$41.61M derived: sum of 3 quarters · filed 2026-03-26 | -$59.17M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$13.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$22.00M derived: sum of 2 quarters · filed 2025-11-05 | -$39.56M 10-Q · filed 2025-11-05 | -$55.67M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$8.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$25.60M 10-Q · filed 2025-08-06 | -$41.71M derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | -$17.56M 10-Q · filed 2025-05-06 | -$33.67M derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | -$16.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$37.93M 10-K · filed 2025-03-12 | ||
| 2023-09-30 | -$21.82M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |